Biotech | August 20, 2021
Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Dr. Reddy's has the rights to distribute 250mn doses in India
Subscribe To Our Newsletter & Stay Updated
